Research News
View articles by month and year
-
Another Study Shows Ten Years of Tamoxifen Better Than Five for Early-Stage, Estrogen-Receptor-Positive Disease
Another large study finds 10 years of tamoxifen are better than 5.
-
SERM Hormonal Therapy Medicines Help Reduce Risk in Women at High Risk, But Aren’t Widely Used
A new study underscores the effectiveness of SERM hormonal therapy medicines to reduce breast cancer risk, but also found that they aren’t widely used because of concerns about side effects.
-
Study Suggests Lack of Vitamin D Production During Winter Months May Make Tamoxifen Less Effective
A study by Canadian researchers suggests that lower vitamin D levels during winter months may interfere with tamoxifen’s effectiveness.
-
High-Risk Women Often Don’t Take Risk-Reducing Medicines Because of Side Effects
A report written for the U.S. Preventive Services Task Force says that many women at high risk of breast cancer don’t take medicines that can lower that risk because of side effects.
-
About 25% of Women Either Don’t Start or Don’t Finish Hormonal Therapy
A study suggests that about 25% of women who are prescribed hormonal therapy to reduce the risk of recurrence after surgery either don’t start taking the medicine or stop taking it early.
-
Femara Better Than Tamoxifen for Certain Types of Breast Cancer
Femara was better than tamoxifen in treating postmenopausal women diagnosed with estrogen-receptor-positive, HER2-negative, lobular breast cancer; it was also better at treating luminal B breast cancers.
-
Ten Years of Tamoxifen Better Than Five for Early-Stage, Estrogen-Receptor-Positive Disease
For women diagnosed with early-stage, estrogen-receptor-positive breast cancer, 10 years of tamoxifen offers more benefits than 5 years.
-
Femara Offers More Benefits Than Tamoxifen After Breast Cancer Surgery
New results boost evidence that postmenopausal women get more benefits from 5 years of Femara compared to 5 years of tamoxifen after surgery for early-stage, hormone-receptor-positive breast cancer.
-
Is Switching Hormonal Therapies Better Than Taking Only One?
Research suggests that taking tamoxifen for 2 to 3 years and then switching to an aromatase inhibitor might be better than taking only tamoxifen or only an aromatase inhibitor for 5 years to reduce recurrence risk and improve overall survival.
-
Tamoxifen Reduces Recurrence Risk for More Than 10 Years
Research has confirmed that tamoxifen reduces breast cancer recurrence risk during the standard 5 years of treatment and that recurrence risk stays lower during the next 5 years after tamoxifen treatment ends.
